Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25433265 | 0.76 | STAT3 (0.39) | STAT3ACHEALOX5UTS2RLMNA | |
| SCHEMBL27228195 | 0.74 | ACHE (0.41) | STAT3L3MBTL1ACHEALOX5ALDH1A1 | |
| SCHEMBL27232066 | 0.74 | ACHE (0.41) | STAT3L3MBTL1ACHEALOX5ALDH1A1 | |
| SCHEMBL10071706 | 0.71 | GRIN2B (0.36) | L3MBTL1ACHEALOX5ALDH1A1 | |
| SCHEMBL30297365 | 0.68 | STAT3 (0.41) | STAT3ACHEALOX5ALDH1A1LMNA | |
| SCHEMBL30297413 | 0.68 | STAT3 (0.41) | STAT3ACHEALOX5ALDH1A1LMNA | |
| SCHEMBL30409224 | 0.67 | CYP19A1 (0.41) | ALDH1A1 | |
| SCHEMBL25436325 | 0.66 | STAT3 (0.40) | STAT3L3MBTL1ACHEALOX5ALDH1A1 | |
| SCHEMBL13777889 | 0.65 | LMNA (0.47) | STAT3ACHEALOX5ALDH1A1LMNA | |
| SCHEMBL31607962 | 0.65 | LMNA (0.47) | STAT3ACHEALOX5ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154090-A1 | PROCESS FOR PREPARING GAMMA,DELTA-UNSATURATED ALDEHYDES DERIVATIVES | FIRMENICH SA (CH) | 2025-05-15 | — | — | US | disclosed |
| EP-4486717-A1 | PROCESS FOR PREPARING GAMMA,DELTA-UNSATURATED ALDEHYDES DERIVATIVES | Firmenich SA (CH) | 2025-01-08 | — | — | EP | disclosed |
| WO-2023166004-A1 | PROCESS FOR PREPARING GAMMA,DELTA-UNSATURATED ALDEHYDES DERIVATIVES | FIRMENICH SA (CH) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154090-A1 | PROCESS FOR PREPARING GAMMA,DELTA-UNSATURATED ALDEHYDES DERIVATIVES | DEGS1, EBP, FASN | STAT3 4420/4885L3MBTL1 4659/4885ACHE 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.